Last updated on June 2020

Evaluate the Efficacy and Safety of Rasburicase (Fasturtec ) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia

Brief description of study

Primary Objective:

To evaluate safety of rasburicase in pediatric patients with NHL and AL

Secondary Objective:

To assess efficacy of rasburicase for prevention and treatment of hyperuricemia

Detailed Study Description

Study duration per participants is approximatively 14 days including a 5-day treatment period.

Clinical Study Identifier: NCT04349306

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.